Reported Earlier, Mesoblast Hits 300-Patient Enrollment Milestone In Pivotal Phase 3 CLBP Trial, With Primary Endpoint Powered For 12-Month Pain Reduction Comparison

뉴스 본문을 불러오고 있어요.

Reported Earlier, Mesoblast Hits 300-Patient Enrollment Milestone In Pivotal Phase 3 CLBP Trial, With Primary Endpoint Powered For 12-Month Pain Reduction Comparison | 웨이프 WAPE

Reported Earlier, Mesoblast Hits 300-Patient Enrollment Milestone In Pivotal Phase 3 CLBP Trial, With Primary Endpoint Powered For 12-Month Pain Reduction Comparison

기사 요약

관련 종목

댓글 —